Determinants of intensive insulin therapeutic regimens in patients with type 1 diabetes: data from a nationwide multicenter survey in Brazil by Gomes, Marilia Brito et al.
METABOLIC SYNDROME
DIABETOLOGY & 
Gomes et al. Diabetology & Metabolic Syndrome 2014, 6:67
http://www.dmsjournal.com/content/6/1/67RESEARCH Open AccessDeterminants of intensive insulin therapeutic
regimens in patients with type 1 diabetes: data
from a nationwide multicenter survey in Brazil
Marilia Brito Gomes1*, Carlos Antonio Negrato2, Roberta Cobas1, Lucianne Righeti Monteiro Tannus1,
Paolla Ribeiro Gonçalves1, Pedro Carlos Barreto da Silva1, João Regis Ivar Carneiro1,
Alessandra Saldanha Mattos Matheus1, Sergio Atala Dib3, Mirela Jobim Azevedo4, Márcia Nery5, Melanie Rodacki6,
Lenita Zajdenverg7, Renan Magalhães Montenegro Junior7, Janice Sepulveda8, Luis Eduardo Calliari9,
Deborah Jezini10, Neuza Braga11, Jorge L Luescher12, Renata S Berardo6, Maria Carmo Arruda-Marques13,
Renata M Noronha14, Thais D Manna15, Roberta Salvodelli15, Fernanda G Penha15, Milton C Foss16,
Maria C Foss-Freitas16, Antonio C Pires17, Fernando C Robles17, Maria de Fátima S Guedes2, Patricia Dualib18,
Saulo C Silva19, Emerson Sampaio20, Rosangela Rea21, Ana Cristina R Faria21, Balduino Tschiedel23,
Suzana Lavigne22, Luis Henrique Canani17, Alessandra T Zucatti17, Marisa Helena C Coral24, Daniela Aline Pereira24,
Luiz Antonio Araujo25, Monica Tolentino26, Hermelinda C Pedrosa18, Flaviane A Prado18, Nelson Rassi27,
Leticia B Araujo27, Reine Marie C Fonseca28, Alexis D Guedes28, Odelissa S Matos28, Catia C Palma1,
Rossana Azulay29, Adriana C Forti30, Cristina Façanha30, Ana Paula Montenegro7, Naira H Melo31, Karla F Rezende31,
Alberto Ramos32, João Soares Felicio33, Flavia M Santos33 and Brazilian Type 1 Diabetes Study Group (BrazDiab1SG)Abstract
Background: To evaluate the determinants of intensive insulin regimens (ITs) in patients with type 1 diabetes
(T1D).
Methods: This multicenter study was conducted between December 2008 and December 2010 in 28 public clinics
in 20 Brazilian cities. Data were obtained from 3,591 patients (56.0% female, 57.1% Caucasian). Insulin regimens
were classified as follows: group 1, conventional therapy (CT) (intermediate human insulin, one to two injections
daily); group 2 (three or more insulin injections of intermediate plus regular human insulin); group 3 (three or more
insulin injections of intermediate human insulin plus short-acting insulin analogues); group 4, basal-bolus (one or
two insulin injections of long-acting plus short-acting insulin analogues or regular insulin); and group 5, basal-bolus
with continuous subcutaneous insulin infusion (CSII). Groups 2 to 5 were considered IT groups.
Results: We obtained complete data from 2,961 patients. Combined intermediate plus regular human insulin was
the most used therapeutic regimen. CSII was used by 37 (1.2%) patients and IT by 2,669 (90.2%) patients. More
patients on IT performed self-monitoring of blood glucose and were treated at the tertiary care level compared to
CT patients (p < 0.001). The majority of patients from all groups had HbA1c levels above the target. Overweight or
obesity was not associated with insulin regimen. Logistic regression analysis showed that economic status, age,
ethnicity, and level of care were associated with IT (p < 0.001).
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Conclusions: Given the prevalence of intensive treatment for T1D in Brazil, more effective therapeutic strategies are
needed for long term-health benefits.
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The incidence of T1D has increased in recent decades in
developed and developing countries, such as Brazil [1,2].
T1D negatively impacts quality and duration of life, due to
morbidity and mortality from chronic complications
which increase the costs of medical care [3-5]. A steady
decline in mortality rates due to end-stage renal disease
and a steady increase in mortality from cardiovascular dis-
ease (CVD) have been observed in recent decades [6,7].
The Diabetes Control and Complications Trial (DCCT)
and its long-term follow-up study, the Epidemiology of Dia-
betes Interventions and Complications (EDIC) Trial, sug-
gested that the mechanisms that underlie the accelerated
atherosclerosis observed in this population are associated
with poor glycemic control [8-10]. However, other factors
related to CVD may contribute to atherosclerosis in pa-
tients with T1D, such as oxidative stress [11], markers of in-
sulin resistance [12], markers of low-grade inflammation
[13], dyslipidemia [14], hypertension [14,15], and obesity
[15]. These findings support the importance of optimizing
glycemic control and CV risk factors to reduce the risk of
diabetes-related complications. However, the few observa-
tional studies that have been conducted with these patients
have demonstrated the difficulty of achieving glycemic con-
trol and CV risk factor targets despite treatment with mul-
tiple daily insulin injections or continuous subcutaneous
insulin infusion (CSII) using a pump [9,15,16].
The SEARCH for Diabetes in Youth Study demon-
strated poor glycemic control, (HbA1c >9.5%), in 17.0%
of these patients and elevated blood pressure in 5.9%
[17,18] emphasizing the difficulty of treating these pa-
tients in daily clinical practice.
The Brazilian Type 1 diabetes Study Group (BrazDiab1SG)
conducted a survey that analyzed the demographic, clin-
ical, and economic data of patients with T1D who received
medical care at public clinics in Brazil. The absence of
Brazilian national data on the determinants of clinical in-
tensive insulin therapeutic regimen (IT) used by patients
with T1D led the BrazDiab1SG to conduct this study to
provide current and reliable data on this topic.Research design and methods
Overview of the Brazilian type 1 diabetes study group
BrazDiab1SG, a retrospective, cross-sectional, multicen-
ter observational study, was conducted from December
2008 to 2010 in 28 public secondary and tertiary care
clinics located in 20 cities in four Brazilian geographicregions (north/northeast, mid-west, southeast, and south).
The data collection methods have been described previ-
ously [19-21]. The inclusion criteria consisted of patients
with a diagnosis of T1D by a physician. All of the patients
received health care and had all the expenses with the
treatment covered by the National Brazilian Health Care
System and all of the eligible participating centers had to
have a diabetes clinic with at least one endocrinologist
and had to provide data from a minimum of 50 consecu-
tive outpatients who regularly attended the clinic. A total
of 3,591 patients who met these criteria were included in
the study. All patients were diagnosed between 1960 and
2010. Patients were excluded if they did not fulfill all of
the inclusion criteria.
Each center’s local ethics committee approved the
study (Appendix 1). Written informed consent was ob-
tained from all of the patients or their parents.Data collection
We collected demographic and economic status data in an
interview (by a questionnaire) during a clinical visit. The
following variables were also recorded: current age; age at
diagnosis; duration of diabetes; blood pressure; insulin
therapeutic regimen; frequency of daily self-monitoring of
blood glucose (SMBG); comorbidities; self-reported fre-
quency of severe hypoglycemia; hospitalization due to dia-
betic ketoacidosis or hyperglycemia and smoking status
(current smoking was defined as smoking more than one
cigarette per day at the time of the interview). Patients
younger than 13 years were considered children, patients
between 13 and 19 years old were classified as adolescents,
and patients older than 19 were considered adults.
The levels of HbA1c, fasting plasma glucose (FPG), total
cholesterol, LDL cholesterol, HDL cholesterol, and triglyc-
erides measured during the last clinical visit were obtained
from the patients’ medical records. Within one year of the
study assessment, patients with a diabetes duration greater
than or equal to five years from diagnosis were screened
for the following chronic diabetes-related complications:
retinopathy (classified as absent, nonproliferative, or pro-
liferative; by fundoscopy); clinical nephropathy (according
to American Diabetes Association (ADA) recommenda-
tions [22]); macrovascular diseases (classified as clinical
coronary artery disease, stroke, and peripheral vascular
disease); and foot pathologies.
The following ADA goals for adequate metabolic and
clinical control [22] were adopted by the BrazDiab1SG.
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mol (7.5%) for patients with T1D between 13 and 19 years
old; <64 mmol/mol (8%) for patients between 6 and
12 years old; between 58 mmol/mol (7.5%) and 69 mmol/
mol (8.5%) for patients <6 years old; and <53 mmol/mol
(7%) for adult patients with T1D [22]. Poor glycemic con-
trol was defined as HbA1c higher than 75 mmol/mol
(9%).
In adults, overweight was defined as a BMI ≥25 kg/m2,
and obesity as a BMI ≥30 kg/m2 [15]. In children and
adolescents, overweight was defined as a BMI ≥85th per-
centile for age and gender, and obesity as a BMI ≥95th
percentile for age and gender [23].
HbA1c values obtained during the last clinical visit
and the measurement methods were collected from the
patients’ medical charts. HbA1c measurements were ob-
tained for 3,097 patients (86.2%) using methods certified
by the National Glycohemoglobin Standardization Pro-
gram (NGSP). Of the total population, 1,652 patients
(53.2%) were evaluated using high-performance liquid
chromatography, whereas 1,445 patients (46.7%) were
evaluated using turbidimetry. The HbA1c measurements
using methods not certified by the NGSP, missing data,
and HbA1c measurements obtained more than one year
before the study assessment were excluded from the gly-
cemic control analyses (n = 494; 13.8%). FPG, triglycerides,
HDL cholesterol, and total cholesterol were measured
using enzymatic techniques . LDL cholesterol level was
calculated using Friedewald’s equation [24].
Insulin therapeutic regimens
Insulin therapeutic regimens were performed according to
the center where patients were treated and to the guide-
lines from Brazilian Diabetes Society (BDS) [25] classified
into the following five groups: group 1, conventional ther-
apy (CT) (intermediate human insulin, one to two injec-
tions daily); groups 2 to 4, patients using three or more
insulin injections daily as follows: group 2, one or two in-
jections of intermediate human insulin plus regular hu-
man insulin; group 3, one or two insulin injections of
intermediate human insulin plus short-acting insulin ana-
logues; group 4, basal-bolus (one or two insulin injections
of long-acting insulin analogues plus short-acting insulin
analogues or long-acting insulin-analogues plus regular in-
sulin); and group 5, basal-bolus with CSII. Groups 2 to 5
were considered IT groups.
Sample calculation and economic status
The study sample represented the distribution of T1D
cases across four geographic regions in Brazil. This dis-
tribution was estimated using the overall population dis-
tribution reported in the 2000 Brazilian Institute of
Geography and Statistics Population Census (IBGE) [26].
These data were combined with the national estimatesof diabetes prevalence, which were derived from a 1988
survey, to determine the minimum number of patients to
be studied in each region [27]. Patient economic status was
defined according to the Brazilian Economic Classification
Criteria [28]. This classification considers educational level,
which is categorized as illiterate/incomplete primary edu-
cation, complete primary education/incomplete secondary
education, complete secondary education/incomplete high
school, complete high school/some college, or complete
college education. The following economic status classifi-
cations were considered for this analysis: high, middle, low,
and very low [28].
Statistical analysis
The data are presented as mean (±SD) values for con-
tinuous variables and as counts (relative frequencies) for
discrete variables. When multiple comparisons were
used, we used the Bonferroni correction. A multivariate
logistic regression model was performed with IT (yes for
groups 2 to 5 and no for CT) as the dependent (out-
come) variable and demographic data, such as gender,
age (stratified as children, adolescents, and adults), eco-
nomic status, self-reported ethnicity (Caucasian or non-
Caucasian), and duration of diabetes, as independent
(exposure) variables. All of the analyses were performed
using the Statistical Package for the Social Sciences
(SPSS version 17.0, SPSS, Inc., Chicago, IL, USA). Odds
ratios (ORs) with 95% confidence intervals (CIs) were
calculated when indicated. A two-sided p < 0.05 was
considered statistically significant.
Results
Overview of participant demographics, socioeconomic
status, and level of care
Data were obtained from 2,961 patients [excluded: n =
630 (17.6%): 494 because of missing HbA1c data and
136 because of missing data about insulin therapeutic
regimens]. The median follow-up time of the 28 centers
was 4.2 years (<1 to 49). The majority of the patients
attended tertiary care centers. We observed that more
patients from groups 3 and 4 had visited the clinic in
the year before the beginning of the study. The eco-
nomic status of 1,977 (69.0%) patients was either very
low or low. The demographic data of the studied popu-
lation are shown in Table 1.
Overview of diabetes treatment modality, glycemic
control, and coexistence of acute and chronic diabetes-
related complications
Combined intermediate plus regular human insulin was
the most frequently used insulin therapeutic regimen.
IT (groups 2 to 5) was being administered to 2,669 pa-
tients (90.2%). More patients who received IT attended
Table 1 Demographic data of the study population
Variable Value
Age, y 19 (1-66)
Gender, F (%) 2,010 (56.0)
Age at diagnosis, y 10.0 (<1 to 44)
Age at diagnosis, y (%)
0-4.9 667 (18.5)
5-9.9 961 (26.8)
10-14.9 941 (26.2)
≥15 1,022 (28.5)
Ethnicity, n (%)
Caucasian 2,049 (57.1)
Non-Caucasian 1,542 (42.9)
Economic status*
High 245 (7.1)
Medium 771 (22.4)
Low 1,163 (33.9)
Very low 1,255 (36.6)
Duration of diabetes, y 7.0 (<1 to 50)
Geographic region (%)
Southeast 1,424 (39.7)
North/northeast 1,113 (31)
South 820 (22.8)
Mid-west 234 (6.5)
Level of care, n (%)
Secondary 995 (27.7)
Tertiary 2,596 (72.3)
y, year; F, female; data are presented as n (%) or
median (minimum/maximum).
*Data available for 3,434 patients; **data available for 3,553 patients.
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CT (p < 0.001).
Overall, the patients from group 1 were older, had
been diagnosed when they were older, were more fre-
quently non-Caucasians, and more frequently had a low
or very low socioeconomic status compared to the pa-
tients from each individual group who received IT.
Three or more daily injections of regular human insu-
lin or short-acting insulin analogues were used by 1,766
(57.1%) patients, and three or more SMBG daily tests
were reported by 2,041 (65.9%) patients. A higher daily
number of SMBG tests was observed in patients who
received IT (groups 2 to 5) than in the patients who
received CT (group 1) (p < 0.001).
The lowest total daily insulin dose/kilogram was noted in
groups 1 and 5 compared to the other groups (p < 0.001).
Considering the total insulin dose the percentage of doses
(bolus) of short-acting in relation to long-acting insulin
analogues for patients from group 4 was greater than thepercentage of doses ( bolus ) of regular or short-acting
insulin analogues in relation to intermediate insulin in
groups 2 and 3, respectively (p < 0.001).
Group 5 [8.3 ± 1.6% (67.7 ± 17.6 mmol/mol)] had
lower HbA1c compared to patients from group 1 [9.2 ±
2.5% (77.1.0 ± 27.4 mmol/mol)], group 2 [9.5 ± 2.4%
(81.0 ± 26.9 mmol/mol)], and group 3 [9.2 ± 2.3% (77.0 ±
25.3 mmol/mol)] (p < 0.01 for each). No difference in
HbA1c was noted between groups 4 and 5 or between
groups 1 and 2. A higher proportion of patients from
groups 1 and 4 compared to patients from group 2 reached
the HbA1c target (p < 0.005). A higher proportion of pa-
tients from group 2 had poor glycemic control compared
to patients from the other groups (p < 0.001).
The use of an insulin regimen was related with the
frequency of severe hypoglycemia and the frequency of
hospitalization due to hyperglycemia or ketoacidosis
(ANOVA; p < 0.001), but no association reached statis-
tical significance after correction for multiple compari-
sons. The frequency of any microvascular complication
was lower in group 3 compared to the other groups
(p < 0.006). Patients from group 5 used more antihyper-
tensive drugs than the other groups (p < 0.05). No dif-
ference was found regarding the use of antidyslipidemic
drugs among all the groups. All these data are shown in
Table 2.
Using multivariate analysis, the adjusted ORs for IT
use showed that the most important variables were level
of care, age, economic status, and ethnicity. The adjusted
model is shown in Table 3.
Overview of frequency of cardiovascular risk factors
Overweight or obesity was observed in 978 patients
(31.6%), and weight status was not statistically related with
the type of insulin regimen. No difference was observed
in systolic blood pressure between the insulin therapeutic
regimen groups. The patients from group 1 presented
higher diastolic blood pressure (73.5 ± 11.9 mmHg), higher
triglycerides (102.7 ± 90.4 mg/dl), lower HDL cholesterol
(49.8 ± 12.1 mg/dl), higher non-HDL cholesterol (121.7 ±
43.1 mg/dl), and higher LDL cholesterol (111.1 ± 35.7 mg/
dl) than the patients from the other groups (p < 0.001).
Group 2 presented higher total cholesterol than the other
groups (172.7 ± 43.5) (p < 0.001). These data are shown in
Table 2.
Discussion
The evaluation of IT determinants in Brazilian patients
with T1D revealed that approximately 90.0% of the pa-
tients with T1D who were treated by an endocrinologist
received ITs. The majority of these patients were treated
at tertiary care centers (university hospitals) and were
using intermediate plus regular human insulin or short-
acting insulin analogues with a lower bolus dose of short-
Table 2 Clinical and laboratory data according to insulin regimen
Intermediate human insulin Long acting plus
short acting or
regular
*CS II P value
Monotherapy Plus regular Plus short acting
Group 1 Group 2 Group 3 Group 4 Group 5
Demographic and economic status data
n 249 1475 627 573 37
Gender F (%) 135 (54.4) 828 (56.2) 371 (59.2) 532 (57.9) 25 (67.6) 0.4
Level of care (tertiary) 138 (55.2) 1020 (69.2) 570 (90.9) 444 (77.5) 30 (81.1) < 0.001
Clinical visits in the previous year 3.8 ± 1.6 4.1 ± 1.6 4.5 ± 1.4 4.2 ± 1.5 4.5 ± 1.6 <0.001
Age, y 26.5 ± 14.5 21.2 ± 10.9 19.3 ± 11.5 21.7 ± 12.4 22.7 ± 9.9 0.001
Duration of DM ,y 10.6 ± 9.8 9.3 ± 7.5 9.6 ± 8.2 10.8 ± 8.5 12.3 ± 7.0 0.001
Age at diagnosis, y 15.8 ± 9.6 11.7 ± 7.7 9.6 ± 7.5 10.9 ± 7.7 10.4 ± 7.3 < 0.001
Ethinicity, y(%)** < 0.001
Caucasian 113 (45) 754 (51.1) 448 (71.5) 414 (72.3) 29 (78.4)
Non caucasian 136 (54.4) 720 (48.9) 179 (28.5) 159 (27.7) 8 (21.6)
Economic status (%)**
High 13 (5.5) 66 (4.5) 42 (7.0) 85 (15.5) 5 (14.3)
Medium 30 (12.8) 265 (18.3) 192 (32.2) 169 (30.8) 19 (54.3)
Low 68 (28.9) 515 (35.6) 214 (35.9) 180 (32.8) 11(31.1)
Very low 125 (52.8) 601 (41.6) 148 (24.8) 115 (20.9) 0
Glycemic control and insulin dose
A1c (%) 9.2 ± 2.5 9.5 ± 2.4 9.2 ± 2.3 8.8 ± 2.0 8.3 ± 1.6 <0.001
A1c (mmol/mol) 77.1 ± 27.4 81.0 ± 26.9 77.0 ± 25.3 72.8 ± 22.4 67.7 ± 17.6 <0.001
A1c (good) n(%) 58 (23.4) 219 (14.9) 118 (18.8) 123(21.5) 9(24.3) <0.001
A1c (poor) n (%) 114 (46.0) 795 (54) 281 (44.8) 209 (36.5) 9 (24.3) <0.001
SMBG/daily 2.5 ± 1.7 2.9 ± 1.6 3.7 ± 1.4 4.0 ± 1.5 5.2 ± 1.6 <0.001
Insulin dose(U/Kg/day) 0.6 ± 0.3 0.9 ± 0.4 0.9 ± 0.3 0.8 ± 0.3 0.7 ± 0.3 0.001
Bolus (%) _ 21.8 ± 11.6 24.5 ± 12.7 33.2 ± 13.9 _ <0.001
Cardiovascular risk factors
sBP (mmHg) 113.8 ± 18.8 110.6 ± 17.3 110.4 ± 15.9 110.9 ± 16.9 116.0 ± 15.3 0.2
dBP (mmHg) 73.5 ± 11.9 71.0 ± 11.5 69.8 ± 10.9 71.2 ± 11.4 72.4 ± 9.1 0.09
Cholesterol (mg/dl) 171.0 ± 43.9 172.7 ± 43.5 165.2 ± 33.9 167.1 ± 37.8 176.8 ± 53.6 < 0.001
Triglycerides (mg/dl) 102.7 ± 90.4 99.1 ± 79.8 78.6 ± 44.5 84.1 ± 55.6 81.2 ± 58.7 < 0.001
HDL cholesterol (mg/dl) 49.8 ± 12.1 51.7 ± 4.5 54.6 ± 13.9 55.6 ± 15.8 63.9 ± 25.3 < 0.001
Non HDL cholesterol (mg/dl) 121.7 ± 43.1 121.0 ± 41.6 110.5 ± 31.5 112.3 ± 34.1 112.7 ± 40.4 < 0.001
LDL-Cholesterol 102.1 ± 35.7 102.3 ± 34.0 95.3 ± 28.0 95.9 ± 30.1 96.6 ± 32.6 < 0.001
BMI (kg/m2) 21.8 ± 4.9 22.0 ± 4.3 21.5 ± 4.1 21.4 ± 3.8 22.6 ± 3.6 0.02
Overweight or obese n(%) 71(28.5) 481 (32.8) 220 (35.1) 164(28.7) 13 (35.1) 0.2
Acute and chronic complications
Severe hypoglycemic, yes (%) 15 (13.3) 157 (18.3) 61 (13.4) 81 (19.4) 3 (8.8) <0.02
Hospitalizations****,yes (%) 41 (16.5) 226 (15.3) 65 (10.4) 66 (11.5) 2 (5.4) 0.004
Microvascular complications, yes (%) 55 (33.7) 259 (26.0) 100 (22.6) 138 (33.5) 14 (43.8) <0.001
The data are presented as counts (percentage), means ± SD or medians (minimum/maximum).
*CSII continuous insulin infusion; * *African-Brazilians, Mulattos, Asians, Native Indians; ***Data were available for 3,434 patients.
****Hospitalization considered for diabetic ketoacidosis or hyperglycemia.
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Table 3 Final adjusted logistic regression model for
intensive insulin therapeutic regimen use and
demographic and economic status of the study
population
n OR (95% CI) Adjusted p-value
Level of care -
Secondary 759 0.39 (0.53-0.71) <0.001
Tertiary 2,202 - Reference
Economic status*
Very low 989 - Reference
High 211 1.52 (2.82-5.20) 0.001
Medium 675 2.19 (3.37-5.19) <0.001
Low 988 1.43 (1.98-2.75) <0.001
Age
1,488 - ReferenceAdults
Adolescents 790 2.53 (3.79-5.68) <0.001
Children 683 1.74 (2.54-3.71) <0.001
Ethnicity
1,758 1.12 (1.49-1.98) <0.001Caucasian
Non-Caucasian† 1,203 Reference
*Data available for 2,863 patients; †African-Brazilians, Mulattos, Asians,
Native Indians.
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used long-acting plus short-acting insulin analogues, and
few patients were using CSII. The use of IT was correlated
with age, economic status, ethnicity, and level of care. In
all of the insulin therapeutic regimen groups, HbA1c was
above the target level in more than 70.0% of the patients.
Additionally, overweight and obesity, which were found in
approximately 31% of the patients, were not directly asso-
ciated with any insulin therapeutic regimen. Although
hospitalization due to diabetic ketoacidosis or hypergly-
cemia and self-reported severe hypoglycemia were related
with the use of insulin therapeutic regimens, no statisti-
cally significant difference in those frequencies was ob-
served between regimens. Our results suggest that it is
necessary to improve diabetes management and optimize
insulin therapeutic regimens in patients with T1D in Brazil
to achieve HbA1c levels within the established targets.
The results of DCCT/EDIC have led to proposals for
intensive management of T1D to improve glycemic con-
trol and avoid or postpone diabetes-related complica-
tions [8,9]. However, several observational studies have
shown that in daily clinical practice, many challenges,
such as social, economic, familial, and psychological fac-
tors, are important barriers to intensive management of
T1D [17,19-21]. A recent observational study conducted
in Germany by Ziegler and colleagues [29] found that an
increase in SMBG frequency above five times daily didnot result in improved metabolic control, as observed in
another study [21]. Ziegler et al. [29] found better gly-
cemic control in patients with T1D who received con-
ventional insulin treatment with three or fewer insulin
injections than in patients who received four or more
insulin injections per day or CSII.
A similar proportion of our patients who received CT
(group 1) achieved the HbA1c targets compared to the
patients from groups 4 and 5, although the latter groups
had lower mean HbA1c and less patients with poor gly-
cemic control. These findings suggest that an inverse
correlation between treatment complexity and glycemic
control could exist in several patients, as demonstrated
in a recently published meta-analysis [30]. This meta-
analysis suggested that adherence is positively correlated
with glycemic control in pediatric patients with T1D.
The weaker post-DCCT association between adherence
and glycemic control suggested that the approach to in-
tensive diabetes management has several shortcomings.
We used the definition of IT that was also used in the
SEARCH study, which is the use of at least three insulin
injections daily [31]. Although other study have consid-
ered an IT to be the use of four or more insulin injec-
tions daily or the use of CSII [29], there is no worldwide
consensus on this definition. The SEARCH study was
a six-center observational study conducted in the USA,
in which youths who used CSII exhibited the lowest
HbA1c. However, similar to our results, more than 70%
of the adolescents, regardless of insulin regimen, had
HbA1c that was unacceptably high [32]. That study con-
cluded that there is a need to more fully assess and under-
stand the factors associated with the insulin regimens
recommended by providers and the influence of race/eth-
nicity, education, and socioeconomic status on these treat-
ment recommendations and to develop more effective
treatment strategies, particularly for adolescents [32].
In the SEARCH study [32], it was found that CSII was
more frequently used by females and patients from high
income classes. The small number of patients using CSII
in our sample did not allow us to analyze this insulin thera-
peutic regimen alone, but it is important to emphasize
that CSII therapy was the most expensive modality of
treatment in our study [3]. However, considering ITs as
a whole, our data show similar results concerning eco-
nomic status, which reflects education level, ethnicity,
and age, but not gender. Additionally, in our study,
self-reported hypoglycemia, hospitalization, and over-
weight or obesity were not related to a specific IT, as
previously described [32]. Moreover, a trend toward a
higher number of SMBG checks performed daily with
more intensive insulin therapeutic regimens was also
noted, as described in another study [29]. Although an
IT is preferred for young patients, the choice of regi-
men must be individualized based on the youth and the
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Considering the cardiovascular risk factors, in general, the
CT patients presented the poorest outcomes. Although
the patients who received CSII had a higher frequency of
microvascular complications and were using more antihy-
pertensive drugs, our cross-sectional study design could
not determine whether the prescription of a given IT or
antihypertensive drugs was due to an already preexisting
diabetes-related complication.
The number of clinical visits was related with the in-
tensity of the insulin therapeutic regimen, which rein-
forced the idea that regular clinic attendance is an
important component of intensive diabetes management
[33]. Strategies must be developed to improve accessibil-
ity to the clinic and to identify those patients who fre-
quently miss appointments [33].
The strengths of our study include a large sample size
that represents the diverse, young Brazilian population
with T1D, which includes a wide range of ethnic groups
and socioeconomic backgrounds from all geographic re-
gions of the country. The data were collected using a
uniform, standardized recruitment protocol in all of the
participating centers; therefore, the data represent a
large occupational cohort.
Finally, several limitations of our study must be ad-
dressed. One limitation was the sample characteristics.
All of the patients lived in large cities and were cared for
by a specialist in a public health center; thus, patients
who relied on primary care facilities and lived in rural
areas may not have been considered. However, this
group of patients with T1D is the minority of those who
receive treatment in Brazil, i.e., fewer than 1%, according
to the survey conducted in 1988 [18]. Another limitation
was the absence of psychosocial evaluation. Family sup-
port and patient self-efficacy have been associated with
several positive outcomes, including better glycemic
control. Self-reported severe hypoglycemia and the ab-
sence of a unique reference laboratory for blood bio-
chemical analysis could be considered other limitations.Conclusions
The majority of our patients did not meet the target for
HbA1c, independent of insulin therapeutic regimen. Simi-
lar number of patients using CT, CSII, and short- and long-
acting insulin analogues reached the target HbA1c. High
economic status was an important determinant of IT use.
Given the high prevalence of aggressive treatments for
T1D currently used in the Brazilian population, more ef-
fective therapeutic strategies and diabetes care pathways
are needed for long-term health benefits.Appendix 1
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